PT2970389T - Composições farmacêuticas - Google Patents

Composições farmacêuticas

Info

Publication number
PT2970389T
PT2970389T PT147245740T PT14724574T PT2970389T PT 2970389 T PT2970389 T PT 2970389T PT 147245740 T PT147245740 T PT 147245740T PT 14724574 T PT14724574 T PT 14724574T PT 2970389 T PT2970389 T PT 2970389T
Authority
PT
Portugal
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PT147245740T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50732290&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2970389(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of PT2970389T publication Critical patent/PT2970389T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
PT147245740T 2013-03-15 2014-03-14 Composições farmacêuticas PT2970389T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361792440P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PT2970389T true PT2970389T (pt) 2020-10-21

Family

ID=50732290

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147245740T PT2970389T (pt) 2013-03-15 2014-03-14 Composições farmacêuticas

Country Status (18)

Country Link
US (3) US11129869B2 (enExample)
EP (2) EP3778623A1 (enExample)
JP (4) JP6538025B2 (enExample)
KR (1) KR102378943B1 (enExample)
CN (3) CN105518021A (enExample)
AU (5) AU2014228460B2 (enExample)
BR (1) BR112015023409B1 (enExample)
CA (2) CA3209602A1 (enExample)
DK (1) DK2970389T3 (enExample)
ES (1) ES2825076T3 (enExample)
FR (1) FR21C1059I2 (enExample)
IL (2) IL288961B1 (enExample)
NL (1) NL301149I2 (enExample)
NO (1) NO2021051I1 (enExample)
PL (1) PL2970389T3 (enExample)
PT (1) PT2970389T (enExample)
RU (1) RU2690377C2 (enExample)
WO (1) WO2014144842A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100734T1 (it) 2011-12-29 2022-03-21 Rhythm Pharmaceuticals Inc Metodo di trattamento di disturbi associati al recettore di melanocortina 4 in portatori eterozigoti
JP6622690B2 (ja) 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
US10835549B2 (en) 2013-04-11 2020-11-17 Vanderbilt University Polyplexes
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
MX2018003983A (es) * 2015-09-30 2018-11-09 Rhythm Pharmaceuticals Inc Metodo de tratamiento de trastornos asociados a la via del receptor de melanocortina-4.
JP6701572B2 (ja) * 2016-07-05 2020-05-27 株式会社リコー インク、収容容器、画像形成方法及び画像形成装置
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
WO2019099735A1 (en) * 2017-11-15 2019-05-23 Rhythm Pharmaceuticals, Inc. Sustained release peptide formulations
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
KR102087634B1 (ko) * 2018-10-11 2020-03-11 (주)바이텍 항비만용 조성물
SG11202106847SA (en) * 2019-01-04 2021-07-29 Kineta Chronic Pain Llc Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN111718408A (zh) * 2020-07-06 2020-09-29 成都圣诺生物制药有限公司 一种Setmelanotide的制备方法
JP2024532294A (ja) * 2021-08-24 2024-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｍｃ４ｒアゴニストペプチド
WO2023080712A1 (ko) * 2021-11-05 2023-05-11 ㈜아이엠디팜 신규한 서방성 지질 전구 제제 및 이를 포함하는 서방성 주사용 약학 조성물
WO2023247999A1 (en) * 2022-06-24 2023-12-28 Mainline Biosciences (Shanghai) Co., Ltd. Peptidic pain modulators and methods for producing and using the same

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
AU6785094A (en) 1993-05-07 1994-12-12 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
CA2433335C (en) * 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
AU2002322466B2 (en) * 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
EA200600055A1 (ru) * 2003-06-19 2006-08-25 Эли Лилли Энд Компани Агонисты рецептора меланокортина 4 (мк4 ) и их применение
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
KR100638041B1 (ko) 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
ES2663916T3 (es) 2005-07-08 2018-04-17 Ipsen Pharma Ligandos de los receptores de la melanocortina
EP1915168A4 (en) 2005-07-08 2010-03-31 Ipsen Pharma LIGANDS OF MELANOCORTIN RECEPTORS
CA2689016C (en) 2007-05-25 2014-08-12 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
EP2979703B1 (en) 2007-11-05 2018-07-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
AR072072A1 (es) * 2008-06-09 2010-08-04 Palatin Technologies Inc Peptidos especificos del receptor de melanocortina para el tratamiento de la obesidad / 669
EP2317975B1 (en) * 2008-06-25 2016-04-13 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
CN101439182B (zh) * 2008-12-18 2012-02-01 北京大学 一种生长抑素受体介导的肿瘤靶向药物组合物
BRPI1009644B1 (pt) * 2009-06-08 2022-02-08 Palatin Technologies, Inc Peptídeo cíclico ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e uso da composição farmacêutica
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
MX2012001513A (es) 2009-08-05 2012-05-22 Ipsen Pharma Sas Uso de melanocortinas para tratar la dislipidemia.
WO2011060355A1 (en) 2009-11-16 2011-05-19 Ipsen Pharma S.A.S Process for the synthesis of ac-arg-cyclo(cys-d-ala-his-d-phe-arg-trp-cys)-nh2
JP5486690B2 (ja) 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
KR102038677B1 (ko) 2011-06-14 2019-10-30 입센 파마 에스.에이.에스 활성 성분으로 멜라노코르틴 수용체 리간드를 함유하는 지속-방출형 조성물
JP2013046596A (ja) 2011-08-29 2013-03-07 Alpha-Nano-Medica Co Ltd 新規な複合体、それを含有する医薬及び癌の治療方法
WO2013033838A1 (en) 2011-09-09 2013-03-14 Pharmagap Inc. Liposomal formulations of cationic peptides and uses thereof
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
JP6622690B2 (ja) * 2013-03-15 2019-12-18 リズム・ファーマシューティカルズ・インコーポレイテッド ペプチド組成物
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物

Also Published As

Publication number Publication date
CA2906782C (en) 2023-10-03
IL241378B (en) 2022-01-01
HK1220702A1 (en) 2017-05-12
PL2970389T3 (pl) 2021-03-08
NO2021051I1 (no) 2024-08-05
FR21C1059I1 (fr) 2022-01-21
AU2014228460A1 (en) 2015-10-01
US20220160818A1 (en) 2022-05-26
IL288961B1 (en) 2026-05-01
JP2025004067A (ja) 2025-01-14
BR112015023409A8 (pt) 2019-12-03
NL301149I2 (nl) 2022-11-24
US11129869B2 (en) 2021-09-28
AU2014228460B2 (en) 2018-11-01
EP3778623A1 (en) 2021-02-17
CN105518021A (zh) 2016-04-20
AU2021202699A1 (en) 2021-05-27
IL241378A0 (en) 2015-11-30
BR112015023409B1 (pt) 2023-11-28
JP2016516062A (ja) 2016-06-02
FR21C1059I2 (fr) 2022-12-02
RU2690377C2 (ru) 2019-06-03
US12285460B2 (en) 2025-04-29
CA3209602A1 (en) 2014-09-18
US20160022764A1 (en) 2016-01-28
WO2014144842A2 (en) 2014-09-18
BR112015023409A2 (pt) 2017-07-18
KR102378943B1 (ko) 2022-03-25
CA2906782A1 (en) 2014-09-18
EP2970389A2 (en) 2016-01-20
IL288961A (en) 2022-02-01
AU2019200101B2 (en) 2021-02-04
JP2019189619A (ja) 2019-10-31
RU2019116003A (ru) 2019-07-17
DK2970389T3 (da) 2020-10-26
EP2970389B1 (en) 2020-08-19
CN115957296A (zh) 2023-04-14
NL301149I1 (enExample) 2021-12-08
AU2023204625A1 (en) 2023-08-03
JP2022065117A (ja) 2022-04-26
RU2015143965A (ru) 2017-04-24
AU2025213562A1 (en) 2025-08-21
KR20160020405A (ko) 2016-02-23
ES2825076T3 (es) 2021-05-14
AU2019200101A1 (en) 2019-01-31
WO2014144842A3 (en) 2015-04-09
CN115957297A (zh) 2023-04-14
JP6538025B2 (ja) 2019-07-03
US20260053885A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
IL288961A (en) Pharmaceutical preparations
PL2943181T3 (pl) Kompozycje farmaceutyczne
SMT201900684T1 (it) Composizione farmaceutica combinata
GB201304662D0 (en) Compositions
ZA201408333B (en) Pharmaceutical compositions
PL3043778T3 (pl) Kompozycje farmaceutyczne zawierające refametinib
GB201608461D0 (en) Compositions
IL241254A0 (en) Pharmaceutical preparations containing everolimus
EP3003324A4 (en) Pharmaceutical compositions
SG11201601477VA (en) Pharmaceutical composition
SG11201509194SA (en) Radiomitigating pharmaceutical formulations
IL242704B (en) Pharmacy preparation
HUP1300496A2 (hu) Stabil kombinációs gyógyszerkészítmény
GB201320962D0 (en) Compositions
ZA201506637B (en) Micronized pharmaceutical compositions
ZA201601645B (en) Bendamustine pharmaceutical compositions
IL244365A0 (en) pharmaceutical preparation
SG11201509114TA (en) Pharmaceutical compositions
GB201304699D0 (en) Pharmaceutical compositions
GB201320959D0 (en) Compositions
GB201321497D0 (en) Pharmaceutical compositions
GB201312851D0 (en) Pharmaceutical compositions
GB201304625D0 (en) New pharmaceutical composition
GB201316662D0 (en) Pharmaceutical Combination
GB201312224D0 (en) Compositions